Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Carcinoma
- Carcinoma, Renal Cell
- Mesothelioma
- Cholangiocarcinoma
- Squamous Cell Carcinoma of Head and Neck
Age: 18 years - 66+
Gender: All
We've found 3 total result s for "Cholangiocarcinoma".
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Age: 18 years - 66+
Gender: All
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Age: 18 years - 66+
Gender: All